Rheumatologists' Agg
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
June 13, 2024 10:16 ET | Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Since 2021, the treatment options for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have expanded with the approval of AstraZeneca’s...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
February 26, 2024 16:05 ET | FibroGen, Inc.
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
Gracell_Logo-new.png
Gracell Biotechnologies Acquisition Completed
February 22, 2024 08:45 ET | Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical...
Gracell_Logo-new.png
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
February 20, 2024 07:45 ET | Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Final Logo-01.png
Viral Gastroenteritis Market Size & Share to Exceed USD 10.2 Billion by 2034, at CAGR of 4.6%. “Conquering the Waves: Breakthroughs in Viral Gastroenteritis Market Surge Toward a Healthier Tomorrow!” – PMI Leads the Way
February 01, 2024 21:00 ET | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Viral Gastroenteritis Market size was valued at about USD 6.8 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Uveal Melanoma Market Size & Share to Exceed USD 2.5 Billion by 2034, at CAGR of 5.9%. "Shining a Light on Innovation: Revolutionizing the Uveal Melanoma Market for Brighter Tomorrows" – PMI Leads the Way
February 01, 2024 20:30 ET | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Uveal Melanoma Market size was valued at about USD 1.5 Billion in 2024 and expected to grow at CAGR of 5.9% to...
Use of SGLT2 Inhibit
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
January 03, 2024 16:13 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Icosavax_Logo.jpg
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
December 12, 2023 02:05 ET | Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Final Logo-01.png
Non-Steroidal Anti-Inflammatory Drugs Market Skyrockets: Witness Impressive US$ 28.7 billion by 2030 and Striking CAGR of 6.0% - By PMI
November 09, 2023 08:30 ET | PMI
Covina, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Report Overview of Non-Steroidal Anti-Inflammatory Drugs Market: Non-Steroidal Anti-Inflammatory Drugs, commonly known as NSAIDs, are a class of...
Spherix Global Insig
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
November 08, 2023 15:37 ET | Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...